Hanson Wade Release: Upcoming World Antibody-Drug Conjugate (ADC) Meeting and Awards in San Diego Highlight California's Growing Cancer Therapeutics Hub
SAN DIEGO, Calif., Oct. 21, 2014 /PRNewswire-iReach/ -- Antibody-drug conjugates (ADCs) are one of the most exciting new classes of cancer therapeutics because they combine the potency of small molecules with the specificity of antibodies. California's culture of innovation, as well as access to world class drug discovery and development expertise, has accelerated progress in ADC therapeutics, a market that was $396 million in 2013 and growing at a rate of 48% per year.1 At the World ADC meeting, held in San Diego from October 26-29, more than 600 antibody-drug conjugate experts will convene, a quarter of these conference attendees hailing from California. World ADC organizers Hanson Wade chose San Diego as a destination specifically to highlight California's significance in the growth of the ADC industry.
Photo - http://photos.prnewswire.com/prnh/20141021/153337
Miles Harley, Director at Hanson Wade, commented "We moved the World ADC meeting to San Diego because so much phenomenal antibody-drug conjugate discovery and development is being done by California-based companies."
South San Francisco, California-based Genentech (NASDAQ: GENE) has the first and most successful ADC oncology drug on the market for breast cancer. Genentech's Andrew Polson, Senior Scientist, Cancer Therapeutics will give program highlights from the company's clinical stage ADCs, nine of which are listed on their website. Genentech's ADC programs will be covered thoroughly at the meeting, with six presentations in the meeting's Discovery Stream, Development Stream, and Chemistry, Manufacturing and Controls (CMC) Stream occurring October 27th-28th, as well as in the Clinical Day (October 29th) and Workshops (October 26th).
Northern California's Genentech is a main sponsor for the World ADC Awards on October 26th, a celebration of advancements in antibody-drug conjugate innovation, drug candidates, teams, and contract services. Igenica, a privately owned company located just south of San Francisco in Burlingame, California is a finalist for the "Best Scientific Innovation" award. While Igenica's cancer therapeutics pipeline is less clinically advanced compared to Genentech's, a strong delegation from the company will be present. Other northern California companies represented at a high level at the meeting include Cellerant Therapeutics, CytomX Therapeutics, ProteinSimple, and Stem CentRx, with many more sending delegates.
Southern California's antibody-drug conjugate contingent will also be well-represented at World ADC by speakers from five leading companies. From the greater Los Angeles area, biologics heavyweight Amgen (NASDAQ: AMGN) will be presenting daily, and its Santa Monica-based neighbor Agensys will present October 29th. San Diego will be represented by Celgene (NASDAQ: CELG), speaking on October 26th, and Sorrento Therapeutics speaking on the 28th.
While the World ADC meeting will highlight the success of California's thriving antibody-drug conjugate hub, it will also be a global event, bringing together cancer therapeutics experts from around the world to discuss the latest technological advancements. The conference is still open for registration, however some workshops have sold out. Press passes for both the conference and the awards ceremony will be issued to journalists and bloggers who can provide proof of employment or contract with a reputable publication. For more information, visit adc-summit.com and www.worldadc-awards.com.
About Hanson Wade:
Hanson Wade specialises in bringing people together through outstanding business conferences and year round community contact. We accelerate growth across industry and across the globe.
We do this by finding the right people, the right issues, and the right answers to deliver commercial results fast and with less risk.
Our team is headquartered in London and works worldwide. Events are held in major global cities across North America, Europe, Africa, the Middle East and South America.
It's a privilege to work with some of the world's leading business, scientific and academic minds. We are proud of the progress we achieve with our clients.
The right collection of people, at the right time, in the right environment can change the world. We work every day to make that happen
1. Antibody Drug Conjugates: Technologies and Global Markets, BCC Research LLC, February 2014, http://www.bccresearch.com/market-research/pharmaceuticals/antibody-drug-conjugates-phm161a.html accessed 10/20/2014.
Media Contact: Katie Draper, Hanson Wade, +44 (0)20 3141 8735, adc@hansonwade.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Help employers find you! Check out all the jobs and post your resume.
Photo - http://photos.prnewswire.com/prnh/20141021/153337
Miles Harley, Director at Hanson Wade, commented "We moved the World ADC meeting to San Diego because so much phenomenal antibody-drug conjugate discovery and development is being done by California-based companies."
South San Francisco, California-based Genentech (NASDAQ: GENE) has the first and most successful ADC oncology drug on the market for breast cancer. Genentech's Andrew Polson, Senior Scientist, Cancer Therapeutics will give program highlights from the company's clinical stage ADCs, nine of which are listed on their website. Genentech's ADC programs will be covered thoroughly at the meeting, with six presentations in the meeting's Discovery Stream, Development Stream, and Chemistry, Manufacturing and Controls (CMC) Stream occurring October 27th-28th, as well as in the Clinical Day (October 29th) and Workshops (October 26th).
Northern California's Genentech is a main sponsor for the World ADC Awards on October 26th, a celebration of advancements in antibody-drug conjugate innovation, drug candidates, teams, and contract services. Igenica, a privately owned company located just south of San Francisco in Burlingame, California is a finalist for the "Best Scientific Innovation" award. While Igenica's cancer therapeutics pipeline is less clinically advanced compared to Genentech's, a strong delegation from the company will be present. Other northern California companies represented at a high level at the meeting include Cellerant Therapeutics, CytomX Therapeutics, ProteinSimple, and Stem CentRx, with many more sending delegates.
Southern California's antibody-drug conjugate contingent will also be well-represented at World ADC by speakers from five leading companies. From the greater Los Angeles area, biologics heavyweight Amgen (NASDAQ: AMGN) will be presenting daily, and its Santa Monica-based neighbor Agensys will present October 29th. San Diego will be represented by Celgene (NASDAQ: CELG), speaking on October 26th, and Sorrento Therapeutics speaking on the 28th.
While the World ADC meeting will highlight the success of California's thriving antibody-drug conjugate hub, it will also be a global event, bringing together cancer therapeutics experts from around the world to discuss the latest technological advancements. The conference is still open for registration, however some workshops have sold out. Press passes for both the conference and the awards ceremony will be issued to journalists and bloggers who can provide proof of employment or contract with a reputable publication. For more information, visit adc-summit.com and www.worldadc-awards.com.
About Hanson Wade:
Hanson Wade specialises in bringing people together through outstanding business conferences and year round community contact. We accelerate growth across industry and across the globe.
We do this by finding the right people, the right issues, and the right answers to deliver commercial results fast and with less risk.
Our team is headquartered in London and works worldwide. Events are held in major global cities across North America, Europe, Africa, the Middle East and South America.
It's a privilege to work with some of the world's leading business, scientific and academic minds. We are proud of the progress we achieve with our clients.
The right collection of people, at the right time, in the right environment can change the world. We work every day to make that happen
1. Antibody Drug Conjugates: Technologies and Global Markets, BCC Research LLC, February 2014, http://www.bccresearch.com/market-research/pharmaceuticals/antibody-drug-conjugates-phm161a.html accessed 10/20/2014.
Media Contact: Katie Draper, Hanson Wade, +44 (0)20 3141 8735, adc@hansonwade.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Help employers find you! Check out all the jobs and post your resume.